Loss of bone density and strength is a common problem in Duchenne muscular dystrophy, and can lead to frequent fractures, chronic spine pain and deformity, and premature loss of ambulation. While standards of care call for monitoring bone density in Duchenne, and intervening with osteoporosis drugs at the first sign of fractures, there is still much unmet medical need to better combat bone fragility in this disease. That is why CureDuchenne is so pleased to help support the efforts of Mesentech, Inc who is developing a novel drug that aims to regenerate bone.
Anand Mehta, MD – Chief Medical Officer, Mesentech
Frank Rauch, MD – Shriner’s Hospital for Children Professor of Pediatrics, McGill University
You’ll be prompted to enter your name and email address to view the recording.